Journal of Thrombosis and Thrombolysis

, Volume 19, Issue 3, pp 173–181

Once-Daily Enoxaparin in The Outpatient Setting Versus Unfractionated Heparin in Hospital for the Treatment of Symptomatic Deep-Vein Thrombosis

Authors

    • Prince of Wales Hospital
    • St. George Clinical SchoolUniversity of New South Wales
    • St. George Hospital
  • Tim A. Brighton
    • St. George Hospital
  • Ross I. Baker
    • Royal Perth HospitalUniversity of Western Australia
  • Peter Thurlow
    • Austin and Repatriation Medical Center
  • Choon H. Lee
    • Nepean Hospital
  • for the ASTH DVT Study Group
Article

DOI: 10.1007/s11239-005-1848-x

Cite this article as:
Chong, B.H., Brighton, T.A., Baker, R.I. et al. J Thromb Thrombolysis (2005) 19: 173. doi:10.1007/s11239-005-1848-x

Abstract

Background: Once- and twice-daily low-molecular-weight heparin administered in hospital have been shown to be effective and safe for treating deep-vein thrombosis. The aim of this study was to compare the efficacy and safety of deep-vein thrombosis treatment using once-daily subcutaneous enoxaparin in the outpatient setting with intravenous unfractionated heparin in hospital.

Methods: This randomized, parallel-group, open-label study was conducted in 18 centers in 4 countries. In total, 298 patients with symptomatic deep-vein thrombosis who were eligible for home treatment were randomized to treatment with enoxaparin in the outpatient setting (1.5 mg/kg subcutaneously once-daily) or unfractionated heparin in hospital (5000 IU bolus and 1250 IU/hour intravenous infusion) for ≥5 days. Clinical endpoints were assessed during a 6-month follow-up period.

Results: Among all patients treated with enoxaparin, there was a trend towards fewer recurrent deep-vein thromboses (1.3% vs. 5.4%; p = 0.060) and pulmonary emboli (1.3% vs. 4.1%; p = 0.17) compared with patients treated with unfractionated heparin. When considering a post-hoc combined endpoint of deep-vein thrombosis and pulmonary embolism, significantly fewer events occurred in the enoxaparin group than in the unfractionated-heparin group (2.7% vs. 8.8%; p = 0.026). The incidences of bleeding events and adverse events in the enoxaparin and unfractionated-heparin groups were similar.

Conclusions: Once-daily subcutaneous enoxaparin in the outpatient setting is at least as effective and as well tolerated as in-hospital intravenous unfractionated heparin for treatment of deep-vein thrombosis.

Key Words

deep-vein thrombosisenoxaparinhome treatmentunfractionated heparin

Copyright information

© Springer Science + Business Media, Inc. 2005